Fine Comparison of the Efficacy and Safety Between GB242 and Infliximab in Patients with Rheumatoid Arthritis: A Phase III Study

INTRODUCTION: This phase III trial (NCT04178850) evaluated the efficacy, safety, and immunogenicity of GB242, an infliximab biosimilar, vs. infliximab (Remicade(®)) reference product in patients with moderate-to-severe active rheumatoid arthritis (RA) combination with methotrexate (MTX) therapy. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yanying, Liu, Shengyun, Liu, Lin, Gong, Xiaowei, Liu, Ju, Sun, Lingyun, Liu, Xiumei, Wu, Lijun, Chen, Linjie, Wang, Ling, Luo, Li, Lin, Jinying, Tie, Ning, Jiang, Zhenyu, Wu, Jian, Lu, Fuai, Sun, Hongsheng, Li, Xiaomei, Yang, Niansheng, Chai, Kexia, Wei, Hua, Da, Zhanyun, Zhao, Cheng, Dai, Lie, Wang, Youlian, Shi, Guixiu, Zhang, Zhenchun, Song, Hui, Guo, Qian, Liu, Yingxue Cathy, Li, Zhanguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814292/
https://www.ncbi.nlm.nih.gov/pubmed/34806155
http://dx.doi.org/10.1007/s40744-021-00396-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814292/
https://www.ncbi.nlm.nih.gov/pubmed/34806155
http://dx.doi.org/10.1007/s40744-021-00396-8

Ejemplares similares